Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...

A Huntsville-based biotechnology company has secured $10 million in funding to begin the trial of a new way to deliver medication to advanced Parkinson’s disease patients. Serina Therapeutics, based ...

Pfizer has ended development of a B7-H4-directed antibody-drug conjugate (ADC), triggering a $1 billion impairment charge. | ...

Pfizer’s metastatic colorectal cancer (mCRC) combination therapy has met one of the primary endpoints of improving ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the ...

Pfizer's Braftovi combination showed significant survival benefits in a Phase 3 study for BRAF V600E-mutant metastatic ...

Pfizer has reported positive outcomes from the Phase III BREAKWATER trial of BRAFTOVI plus cetuximab and mFOLFOX6 for ...

Pfizer (PFE) reported fourth quarter and full-year 2024 earnings results Tuesday, narrowly beating Wall Street expectations ...

Less than two months after an accelerated approval from the FDA, a drug combination featuring Pfizer’s Braftovi has turned in ...

Pfizer (PFE) colorectal cancer therapy Braftovi as part of a drug combo indicates a favorable objective response rate in a ...

Pfizer has announced that its Braftovi (encorafenib) regimen significantly improved both progression-free and overall ...

Pfizer (PFE) announced positive topline results from the progression-free survival – PFS – analysis of the Phase 3 BREAKWATER study of Braftovi ...